Consequently, our study aimed to compare the efficacy and safety of first-line and second/further-line therapies in treating postmenopausal female patients with HR + /HER2 − advanced breast cancer, using an adjusted indirect comparison under a Bayesian framework that assumes non-PH. The gene discussed is ERBB2; the disease is breast carcinoma.